By Drug Class:
The market is segmented based on drug class into chemotherapy, immunotherapy, and others. Chemotherapeutics are further segmented into antimetabolites and alkylating agents. Immune therapeutics are divided into Biologic Response Modifiers (BRF), Colony Stimulating Factors (CSF), tumour vaccines, and monoclonal antibodies.
Immunotherapy led the colorectal cancer therapeutics market because of fewer adverse effects as compared to chemotherapeutics. Non-specificity, toxic side effects, and development of resistance associated with chemotherapy are the hindrance factors for the segment.
By Distribution Channel:
On the basis of distribution channel, the colorectal cancer drugs market can be segmented into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment is expected to have the dominant share in the forecast period because these medications are often prescribed after a thorough diagnosis which are conducted at these institutions.
Retail pharmacies segment is anticipated to hold the second largest share. Because of instances of re-filling of prescriptions, these institutions are able to provide more efficient facilities. Online pharmacies segment is anticipated to experience the highest CAGR due to the increasing usage of online pharmacy facilities, which are gaining popularity due to their ease and convenience.
Some of the key players are Amgen, Bayer, Bristol-Myers Squibb, Eli Lilly, Merck, Roche, and Sanofi. This dominance is due to strong oncology product portfolio, robust pipeline candidates, and key strategic decisions.